The Latin America, Middle East and Africa Enteric Disease Testing Market should witness market growth of 6.0% CAGR during the forecast period (2023-2029).
The untapped market potential in developing nations offers a significant chance for healthcare enterprises to create cutting-edge and affordable testing solutions to meet the unmet needs of the populace. The rise in the popularity of enteric disease testing, increased awareness of the diagnosis of enteric disease testing in emerging economies, a rise in disposable income, an increase in funding, and the discovery and development of efficient enteric disease testing products are other factors that contribute to the industry's expansion.
Innovations in technology and government backing in emerging economies are key market drivers. The market's expansion is also anticipated to be fueled by the expanding demand for early diagnostics. The culture approach, which required expert personnel and took time, formed the foundation of the conventional diagnosis process for enteric infections. Over the past ten years, the market has undergone a revolution owing to the advent of molecular diagnostics as well as additional diagnostic technologies. The demand for early diagnosis of these disorders is anticipated to increase due to the rising mortality rate brought on by these conditions and the affordability of technologically sophisticated diagnostic devices.
Brazil is projected to offer significant opportunities for growth in the near future. The economic and political stability in Brazil has resulted in favorable economic growth. In addition, implementing healthcare reforms, including the Unified Health System (SUS), has provided cost-free healthcare amenities to individuals across all levels. This has been achieved without any additional charges being levied on the beneficiaries. The SUS comprises a blend of healthcare services from both the public and private sectors, as well as supplementary sources. The market is being boosted by supportive government initiatives, including the nation's collaboration on biomedical research aimed at accelerating research and development in diagnosing and treating infectious diseases. These factors are propelling the regional market's growth significantly.
The Brazil market dominated the LAMEA Enteric Disease Testing Market by Country 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $85.3 million by 2029. The Argentina market is anticipated to grow at a CAGR of 6.6% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 5.7% during (2023-2029).
Based on End-user, the market is segmented into Hospital Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. Based on Disease Type, the market is segmented into Bacterial, Viral and Parasitic. Based on Product Type, the market is segmented into Reagents & Consumables and Equipment. Based on Technique, the market is segmented into Immunodiagnostics and Molecular Diagnostics. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TÜV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
The untapped market potential in developing nations offers a significant chance for healthcare enterprises to create cutting-edge and affordable testing solutions to meet the unmet needs of the populace. The rise in the popularity of enteric disease testing, increased awareness of the diagnosis of enteric disease testing in emerging economies, a rise in disposable income, an increase in funding, and the discovery and development of efficient enteric disease testing products are other factors that contribute to the industry's expansion.
Innovations in technology and government backing in emerging economies are key market drivers. The market's expansion is also anticipated to be fueled by the expanding demand for early diagnostics. The culture approach, which required expert personnel and took time, formed the foundation of the conventional diagnosis process for enteric infections. Over the past ten years, the market has undergone a revolution owing to the advent of molecular diagnostics as well as additional diagnostic technologies. The demand for early diagnosis of these disorders is anticipated to increase due to the rising mortality rate brought on by these conditions and the affordability of technologically sophisticated diagnostic devices.
Brazil is projected to offer significant opportunities for growth in the near future. The economic and political stability in Brazil has resulted in favorable economic growth. In addition, implementing healthcare reforms, including the Unified Health System (SUS), has provided cost-free healthcare amenities to individuals across all levels. This has been achieved without any additional charges being levied on the beneficiaries. The SUS comprises a blend of healthcare services from both the public and private sectors, as well as supplementary sources. The market is being boosted by supportive government initiatives, including the nation's collaboration on biomedical research aimed at accelerating research and development in diagnosing and treating infectious diseases. These factors are propelling the regional market's growth significantly.
The Brazil market dominated the LAMEA Enteric Disease Testing Market by Country 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $85.3 million by 2029. The Argentina market is anticipated to grow at a CAGR of 6.6% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 5.7% during (2023-2029).
Based on End-user, the market is segmented into Hospital Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. Based on Disease Type, the market is segmented into Bacterial, Viral and Parasitic. Based on Product Type, the market is segmented into Reagents & Consumables and Equipment. Based on Technique, the market is segmented into Immunodiagnostics and Molecular Diagnostics. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TÜV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
Scope of the Study
By End-user
- Hospital Laboratories
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
By Disease Type
- Bacterial
- Viral
- Parasitic
By Product Type
- Reagents & Consumables
- Equipment
By Technique
- Immunodiagnostics
- Molecular Diagnostics
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- SGS S.A.
- Eurofins Scientific SE
- Bureau Veritas S.A.
- Intertek Group PLC
- TÜV Nord Group
- PerkinElmer, Inc.
- Becton, Dickinson and Company
- Neogen Corporation
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Enteric Disease Testing Market by End User
Chapter 5. LAMEA Enteric Disease Testing Market by Disease Type
Chapter 6. LAMEA Enteric Disease Testing Market by Product Type
Chapter 7. LAMEA Enteric Disease Testing Market by Technique
Chapter 8. LAMEA Enteric Disease Testing Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- SGS S.A.
- Eurofins Scientific SE
- Bureau Veritas S.A.
- Intertek Group PLC
- TÜV Nord Group
- PerkinElmer, Inc.
- Becton, Dickinson and Company
- Neogen Corporation
Methodology
LOADING...
